Madhu Katikineni, MD
Endocrinology, Diabetes & Metabolism · Riverdale, MDNPI 1235182163
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Lilly USA, LLC at 30.8% of the total. Reporting peaked in 2019 at $808 and has fallen 71.2% since, to $232 in 2025.
Across 134 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$723
- Novo Nordisk$373
- AstraZeneca$328
- Sanofi-aventis U.S. LLC$238
- Merck$223
- Boehringer Ingelheim$96
- plus $363 from 11 others
Across 5 payments — averaging $13,200 each. An ownership or investment interest held by the physician or an immediate family member.
- Centerline Biomedical Inc.$66K
What the payments were for
- Food & beverage$2,335100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 34 | $723 |
| Novo Nordisk | 23 | $373 |
| AstraZeneca | 18 | $328 |
| Sanofi-aventis U.S. LLC | 13 | $238 |
| Merck | 23 | $223 |
| Boehringer Ingelheim | 6 | $96 |
| Corcept Therapeutics | 3 | $58 |
| Echosens North America, Inc. | 1 | $57 |
| Abbott | 2 | $44 |
| Cequr Corporation | 2 | $40 |
| Bayer | 2 | $37 |
| Globus Medical | 2 | $31 |
| Digital Diagnostics Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 1 | $21 |
| Amgen | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$2,343 in reported general payments places this provider in the 55th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $106,062 |
| FarxigaDapagliflozin Propanediol | 72 | $93,913 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $34,600 |
| JardianceEmpagliflozin | 22 | $33,254 |
| MounjaroTirzepatide | 26 | $31,660 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $23,969 |
| RybelsusSemaglutide | 11 | $22,469 |
| JanuviaSitagliptin Phosphate | 11 | $17,119 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $11,136 |
| Novolog FlexpenInsulin Aspart | 18 | $3,515 |
| Levothyroxine Sodium | 237 | $3,007 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 23 | $2,484 |
| SynthroidLevothyroxine Sodium | 38 | $2,473 |
| Pantoprazole Sodium | 29 | $1,800 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $373 | $128,53171 claims |
| AstraZenecaFarxiga | $328 | $93,91372 claims |
| Boehringer IngelheimJardiance | $96 | $33,25422 claims |
| Lilly USA, LLCMounjaro | $723 | $31,66026 claims |
| MerckJanuvia | $223 | $17,11911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Riverdale
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.